首页 | 本学科首页   官方微博 | 高级检索  
     


Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring
Authors:Xi-De Wang  Karen Reeves  Feng R Luo  Li-An Xu  Francis Lee  Edwin Clark  Fei Huang
Affiliation:(1) Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, 08543, New Jersey, USA
Abstract:

Background  

Dasatinib is a potent, multi-targeted kinase inhibitor that was recently approved for treatment of chronic myelogenous leukemia resistant to imatinib. To aid the clinical development of dasatinib in prostate cancer, we utilized preclinical models to identify potential molecular markers for patient stratification and efficacy monitoring.
Keywords:
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号